Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome

Search Title by author or title

Session Details

Session Title: Cataract Surgery & Retinal Complications

Session Date/Time: Tuesday 25/09/2018 | 16:30-18:00

Paper Time: 17:02

Venue: Room A3, Podium 1

First Author: : H.Güçlü TURKEY

Co Author(s): :                        

Abstract Details


To compare safety and efficacy of intravitreal dexamethasone implant (IVD) with topical nepafenac 0.1% (TN) in previously untreated Irvine-Gass syndrome (IGS) in clinical practice.


Trakya University Faculty of Medicine


This is a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens implantation (IOL). None of the patients used treatment before IVD or TN. Best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study chart(ETDRS), slit-lamp, intraocular pressure (IOP) measurement, fundus examination, spectral-domain optical coherence tomography (OCT) and fundus florescein angiography were performed to all subjects at baseline,1,3 and 6 month.


The mean BCVA of the patients was 49.3±6.8 ETDRS letters, the mean BCVA was 32.9±7.3 ETDRS letters in post-treatment month 6 after IVD, and TN respectively. The mean central macular thickness (CRT) was 266.6±53.5 μm in post-treatment month 6 in IVD group and the mean CRT was 364.9±56.3 μm in in post-treatment month 6 in TN group. Baseline BCVA has a positive correlation with the post-treatment BCVA in post-treatment month 6 in TN group. There was no correlation between baseline BCVA and post-treatment BCVA in post-treatment month 6 in IVD group.


IVD was found to be better than TN in controlling pseudophakic macular edema and improving visual acuity.

Financial Disclosure:


Back to previous